← Leaderboards
David Alland
Rutgers Biomedical And Health Sciences
$97,558,393
Attributed
$151,531,227
Total exposure
46
Grants
31
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$201,193,652 · 49
By mechanism
U19$72,649,948 · 15
R01$69,679,454 · 20
U01$33,009,779 · 4
UC7$12,462,803 · 1
G20$5,241,770 · 1
R42$3,983,527 · 1
Top collaborators
- Padmini Salgame74 shared
- Jerrold J. Ellner42 shared
- Susan E Dorman17 shared
- Veronique Dartois13 shared
- C Robert Horsburgh13 shared
- David Louis Horn8 shared
- Mark Patrick Nicol6 shared
- Radojka Savic5 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Stephan K Schwander$5,685,114
- Padmini Salgame$42,479,907
- Swetha Kodali$97,392
- Yingda Linda Xie$3,587,896
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisPharmaceutical PreparationsDrug ResistanceBacteriaTuberculosis TreatmentSamplingProgramsBaseDesignInfectionLaboratoriesInnovationDiagnosticTuberculosis DrugsDetectionUnited States National Institutes Of HealthCellsDiagnosisPreventMutationSputumRelapseIsoniazid
Grant awards (200)
Resources, Workforce Development, and Animal Models for the Rutgers RBL$4,302,711
UC7 · FY2025 · AI · contact PI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,722,689
U19 · FY2025 · AI · contact PI
FEND-TB$2,593,818
R01 · FY2025 · AI
Bacteria and Host in TB Transmission$1,612,367
R01 · FY2025 · AI · contact PI
Transmission Links and Clinical Spectrum of Exhaled Mycobacterium Tuberculosis$1,032,233
R01 · FY2025 · AI
Lead Optimization and Preclinical Development of a small molecule inhibitor of M. avium KasA$944,067
U19 · FY2025 · AI · contact PI
Unraveling the spectrum of intrabacterial amide hydrolysis to develop new classes of pyrazinoic acid prodrugs against pyrazinamide resistant Mycobacterium tuberculosis$813,373
R01 · FY2025 · AI · contact PI
Near patient detection of pathogenic candida species directly from blood and urine for rapid treatment response$778,511
U19 · FY2025 · AI · contact PI
Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.$758,976
R01 · FY2025 · AI · contact PI
Nanoreactor beads for POC TB resistance testing$686,998
R01 · FY2025 · AI · contact PI
FEND-TB$298,587
R01 · FY2025 · AI
FEND-TB$196,955
R01 · FY2025 · AI
Administrative Core$107,770
U19 · FY2025 · AI · contact PI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$38,013
U19 · FY2025 · AI · contact PI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$8,125
U19 · FY2025 · AI · contact PI
Resources, Workforce Development, and Animal Models for the Rutgers RBL$4,189,403
UC7 · FY2024 · AI · contact PI
FEND for TB$3,689,474
U01 · FY2024 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,749,420
U19 · FY2024 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,142,223
R01 · FY2024 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,613
R01 · FY2024 · AI
Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions.$796,700
R01 · FY2024 · AI · contact PI
Simple and rapid POC detection for fungemia$764,715
R01 · FY2024 · AI · contact PI
Nanoreactor beads for POC TB resistance testing$701,248
R01 · FY2024 · AI · contact PI
Administrative Core$400,125
U19 · FY2024 · AI · contact PI
Resources, Workforce Development, and Animal Models for the Rutgers RBL$3,970,689
UC7 · FY2023 · AI · contact PI
FEND for TB$3,943,297
U01 · FY2023 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,658,286
U19 · FY2023 · AI · contact PI
Bacteria and Host in TB Transmission$1,697,099
R01 · FY2023 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,088,847
R01 · FY2023 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,613
R01 · FY2023 · AI
Simple and rapid POC detection for fungemia$764,715
R01 · FY2023 · AI · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$724,769
R01 · FY2023 · AI
Development of novel anti-TB drugs that inhibit cell wall biosynthesis and respiration$629,538
U19 · FY2023 · AI · contact PI
Administrative Core$460,254
U19 · FY2023 · AI · contact PI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$339,935
U19 · FY2023 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$219,999
R01 · FY2023 · AI
FEND for TB$4,167,230
U01 · FY2022 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,658,286
U19 · FY2022 · AI · contact PI
Supplement to G20AI67347 to complete critical upgrades to the Rutgers RBL$1,913,331
G20 · FY2022 · AI · contact PI
Bacteria and Host in TB Transmission$1,816,206
R01 · FY2022 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,122,443
R01 · FY2022 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,257
R01 · FY2022 · AI
Simple and rapid POC detection for fungemia$764,715
R01 · FY2022 · AI · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$742,896
R01 · FY2022 · AI
Development of novel anti-TB drugs that inhibit cell wall biosynthesis and respiration$651,550
U19 · FY2022 · AI · contact PI
TB detection in children using a novel stool-based GeneXpert assay$623,129
R01 · FY2022 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$219,999
R01 · FY2022 · AI
Bacteria and Host in TB Transmission$219,999
R01 · FY2022 · AI · contact PI
FEND for TB supplement to accelerate BLINK X development$218,451
U01 · FY2022 · AI
Administrative Core$138,047
U19 · FY2022 · AI · contact PI
FEND for TB$3,954,651
U01 · FY2021 · AI
Key Facility Upgrades for the Rutgers University RBL.$3,328,439
G20 · FY2021 · AI · contact PI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,751,534
U19 · FY2021 · AI · contact PI
Bacteria and Host in TB Transmission$1,695,066
R01 · FY2021 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,119,258
R01 · FY2021 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,107
R01 · FY2021 · AI
Simple and rapid POC detection for fungemia$777,001
R01 · FY2021 · AI · contact PI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$749,427
R01 · FY2021 · AI
Development of novel anti-TB drugs that inhibit cell wall biosynthesis and respiration$652,628
U19 · FY2021 · AI · contact PI
TB detection in children using a novel stool-based GeneXpert assay$448,870
R01 · FY2021 · AI · contact PI
TB detection in children using a novel stool-based GeneXpert assay$192,373
R01 · FY2021 · AI · contact PI
Administrative Core$136,906
U19 · FY2021 · AI · contact PI
FEND for TB$3,998,028
U01 · FY2020 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,457,326
U19 · FY2020 · AI
Administrative Core$2,264,304
U19 · FY2020 · AI
Bacteria and Host in TB Transmission$1,637,992
R01 · FY2020 · AI · contact PI
Novel and Optimized Diagnostics for Pediatric TB$1,085,066
R01 · FY2020 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$851,389
R01 · FY2020 · AI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$776,254
R01 · FY2020 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$770,673
U19 · FY2020 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$661,749
U19 · FY2020 · AI
Novel Biomarkers to Shorten TB Treatment$659,830
R01 · FY2020 · AI · contact PI
Development of novel anti-TB drugs that inhibit cell wall biosynthesis and respiration$647,019
U19 · FY2020 · AI · contact PI
Clinical Core$618,699
U19 · FY2020 · AI
Simple and rapid POC detection for fungemia$605,037
R01 · FY2020 · AI · contact PI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$556,523
R01 · FY2020 · AI
TB detection in children using a novel stool-based GeneXpert assay$536,775
R01 · FY2020 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$525,694
U19 · FY2020 · AI · contact PI
Acquisition of the ECHO 650 liquid handler: a multi-disciplinary, multi-laboratory tool for research, innovation and education$379,300
S10 · FY2020 · OD · contact PI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,665,571
U19 · FY2019 · AI
Administrative Core$1,947,556
U19 · FY2019 · AI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$1,180,603
R01 · FY2019 · AI
Identifying Optimal Treatment Strategies for Tuberculosis Treatment$786,787
R01 · FY2019 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$777,574
U19 · FY2019 · AI
Novel Biomarkers to Shorten TB Treatment$709,366
R01 · FY2019 · AI · contact PI
Development of novel anti-TB drugs that inhibit cell wall biosynthesis and respiration$678,901
U19 · FY2019 · AI · contact PI
TB detection in children using a novel stool-based GeneXpert assay$528,819
R01 · FY2019 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$470,784
U19 · FY2019 · AI · contact PI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$267,556
U19 · FY2019 · AI
Clinical Core$202,101
U19 · FY2019 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$2,399,184
U19 · FY2018 · AI
Administrative Core$1,965,726
U19 · FY2018 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$1,413,190
U19 · FY2018 · AI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$1,325,755
R01 · FY2018 · AI
Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb$1,130,467
R01 · FY2018 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$786,135
R01 · FY2018 · AI · contact PI
Novel Biomarkers to Shorten TB Treatment$725,266
R01 · FY2018 · AI · contact PI
TB detection in children using a novel stool-based GeneXpert assay$549,263
R01 · FY2018 · AI · contact PI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$532,945
U19 · FY2018 · AI
Administrative Core$515,303
U19 · FY2018 · AI
Discovery and Validation of Drug Targets in Vulnerable Populations$478,857
R33 · FY2018 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$385,878
U19 · FY2018 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$348,070
U19 · FY2018 · AI · contact PI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$344,415
U19 · FY2018 · AI
Process and pathway based discovery of novel anti-TB drugs$312,392
U19 · FY2018 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$264,427
U19 · FY2018 · AI
Process and pathway based discovery of novel anti-TB drugs$256,585
U19 · FY2018 · AI · contact PI
In Vitro Screening Core$186,260
U19 · FY2018 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$158,055
U19 · FY2018 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$106,673
U19 · FY2018 · AI
Clinical Core$24,317
U19 · FY2018 · AI
Clinical Core$15,491
U19 · FY2018 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,064,926
U19 · FY2017 · AI
Accuracy of the Xpert Ultra for Diagnosis of Pulmonary Tuberculosis$1,424,115
R01 · FY2017 · AI
Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb$1,134,247
R01 · FY2017 · AI · contact PI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$924,431
U19 · FY2017 · AI
Administrative Core$838,137
U19 · FY2017 · AI
De facto monotherapy during multidrug TB treatment and emergence of resistance$788,371
R01 · FY2017 · AI
Novel Biomarkers to Shorten TB Treatment$728,068
R01 · FY2017 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$587,529
U19 · FY2017 · AI
Process and pathway based discovery of novel anti-TB drugs$493,771
U19 · FY2017 · AI · contact PI
Discovery and Validation of Drug Targets in Vulnerable Populations$478,857
R33 · FY2017 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$454,429
U19 · FY2017 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$216,253
U19 · FY2017 · AI
Clinical Core$44,147
U19 · FY2017 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,078,872
U19 · FY2016 · AI
Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb$1,130,467
R01 · FY2016 · AI · contact PI
On demand blood tests for select agent diagnosis$1,076,572
R01 · FY2016 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$1,072,858
R01 · FY2016 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$1,054,927
U19 · FY2016 · AI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$1,028,211
U19 · FY2016 · AI · contact PI
Novel Biomarkers to Shorten TB Treatment$672,409
R01 · FY2016 · AI · contact PI
Validation and Application of a Model for Human-like TB Latency in Rabbits$543,503
U19 · FY2016 · AI
Administrative Core$516,336
U19 · FY2016 · AI
Discovery and Validation of Drug Targets in Vulnerable Populations$493,607
R33 · FY2016 · AI · contact PI
Process and pathway based discovery of novel anti-TB drugs$462,116
U19 · FY2016 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$255,998
U19 · FY2016 · AI
Clinical Core$74,224
U19 · FY2016 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,050,511
U19 · FY2015 · AI
On demand blood tests for select agent diagnosis$1,485,259
R01 · FY2015 · AI · contact PI
Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb$1,284,246
R01 · FY2015 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$1,192,956
U19 · FY2015 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$788,126
R01 · FY2015 · AI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$757,912
U19 · FY2015 · AI
Administrative Core$725,396
U19 · FY2015 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$606,449
U19 · FY2015 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$468,455
U19 · FY2015 · AI
Process and pathway based discovery of novel anti-TB drugs$441,537
U19 · FY2015 · AI · contact PI
Supplement request for Ebola diagnostic assay development$223,021
R01 · FY2015 · AI · contact PI
Discovery and validation of drug targets in vulnerable pathways of Mtb$218,623
R21 · FY2015 · AI · contact PI
Clinical Core$27,211
U19 · FY2015 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,143,754
U19 · FY2014 · AI
Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant Mtb$1,549,810
R01 · FY2014 · AI · contact PI
Bacterial Mechanisms and Host Pharmacokinetic Factors that Determine Persistence$1,086,119
U19 · FY2014 · AI · contact PI
On demand blood tests for select agent diagnosis$1,073,392
R01 · FY2014 · AI · contact PI
De facto monotherapy during multidrug TB treatment and emergence of resistance$802,715
R01 · FY2014 · AI
Administrative Core$634,424
U19 · FY2014 · AI
Biomarkers to Stratify Risk of Progression from Latent TB Infection to Active$510,579
U19 · FY2014 · AI
Process and pathway based discovery of novel anti-TB drugs$444,101
U19 · FY2014 · AI · contact PI
Biomarkers of Persistent TB Infection and TB Treatment Relapse$435,831
U19 · FY2014 · AI
Validation and Application of a Model for Human-like TB Latency in Rabbits$382,748
U19 · FY2014 · AI
Discovery and validation of drug targets in vulnerable pathways of Mtb$218,623
R21 · FY2014 · AI · contact PI
Clinical Core$94,053
U19 · FY2014 · AI
On demand blood tests for select agent diagnosis$986,226
R01 · FY2013 · AI · contact PI
Development of a second generation MDR-XDR TB assay$538,528
U01 · FY2013 · AI · contact PI
Rapid Diagnosis of XDR Tuberculosis$493,460
R01 · FY2013 · AI · contact PI
Development of a second generation MDR-XDR TB assay$293,902
U01 · FY2013 · AI · contact PI
On demand blood tests for select agent diagnosis$25,902
R01 · FY2013 · AI · contact PI
Development of a second generation MDR-XDR TB assay$1,656,910
U01 · FY2012 · AI · contact PI
On demand blood tests for select agent diagnosis$1,266,188
R01 · FY2012 · AI · contact PI
Rapid Diagnosis of XDR Tuberculosis$522,236
R01 · FY2012 · AI · contact PI
Development of a second generation MDR-XDR TB assay$1,754,517
U01 · FY2011 · AI · contact PI
Rapid Diagnosis of XDR Tuberculosis$718,373
R01 · FY2011 · AI · contact PI
Development of a second generation MDR-XDR TB assay$1,631,422
U01 · FY2010 · AI · contact PI
Rapid Diagnosis of XDR Tuberculosis$528,832
R01 · FY2010 · AI · contact PI
AFB Smears for Drug Resistance Detection and Surveillance in MTb.$500,000
RC1 · FY2010 · AI · contact PI
Integrated Dual-Use Systems for Bio-Defense & Sepsis Diagnosis$450,153
U01 · FY2010 · AI · contact PI
Development of a Molecular Blood Culture$390,000
R01 · FY2010 · AI · contact PI
Development of a second generation MDR-XDR TB assay$1,343,464
U01 · FY2009 · AI · contact PI
Rapid Diagnosis of XDR Tuberculosis$527,054
R01 · FY2009 · AI · contact PI
AFB Smears for Drug Resistance Detection and Surveillance in MTb.$500,000
RC1 · FY2009 · AI · contact PI
Integrated Dual-Use Systems for Bio-Defense & Sepsis Diagnosis$445,977
U01 · FY2009 · AI · contact PI
Development of a Molecular Blood Culture$390,000
R01 · FY2009 · AI · contact PI
Integrated Dual-Use Systems for Bio-Defense & Sepsis Diagnosis$98,607
U01 · FY2009 · AI · contact PI
Sample Processing Cartridges for Rapid PCR TB Detection$1,160,774
R42 · FY2008 · AI · contact PI
Integrated Dual-Use Systems for Bio-Defense & Sepsis Diagnosis$434,892
U01 · FY2008 · AI · contact PI
Sample Processing Cartridges for Rapid PCR TB Detection$1,343,564
R42 · FY2007 · AI · contact PI
Detection of Select Agents in Single-Well Assays$873,498
U01 · FY2007 · AI · contact PI
Integrated Dual-Use Systems for Bio-Defense & Sepsis Diagnosis$446,009
U01 · FY2007 · AI · contact PI
Sample Processing Cartridges for Rapid PCR TB Detection$1,479,189
R42 · FY2006 · AI · contact PI
Detection of Select Agents in Single-Well Assays$875,630
U01 · FY2006 · AI · contact PI
Towards drugs that prevent resistance to the HIV OI, TB$186,014
R21 · FY2006 · AI · contact PI
Detection of Select Agents in Single-Well Assays$872,892
U01 · FY2005 · AI
TUBERCULOSIS GENOTYPING AND EVOLUTIONARY CONSORTIUM$499,628
R01 · FY2005 · AI
Towards drugs that prevent resistance to the HIV OI, TB$229,365
R21 · FY2005 · AI
Detection of Select Agents in Single-Well Assays$852,212
U01 · FY2004 · AI
POPULATION BASED INVESTIGATIONS OF TUBERCULOSIS$518,849
R01 · FY2004 · AI
TUBERCULOSIS GENOTYPING AND EVOLUTIONARY CONSORTIUM$486,313
R01 · FY2004 · AI
POPULATION BASED INVESTIGATIONS OF TUBERCULOSIS$523,512
R01 · FY2003 · AI
TUBERCULOSIS GENOTYPING AND EVOLUTIONARY CONSORTIUM$480,296
R01 · FY2003 · AI